Latest Us Market News

Galilee Energy has secured an option to acquire the Zydeco Gas Project in Louisiana, marking a strategic expansion into the US market, supported by a A$6.5 million capital raise to accelerate development.

Proteomics International Laboratories has clarified that no undisclosed information explains its recent share price jump, pointing instead to recent Medicare reimbursement decisions and key product developments.

Evion Group has landed a significant A$1.5 million order to supply expandable graphite to a major US graphite supply chain company, reinforcing its position as a trusted non-Chinese supplier amid growing demand.

Singular Health has submitted a 510(k) premarket notification to the FDA for its enhanced 3DICOM MD Cloud platform, aiming to expand imaging capabilities and introduce a scalable, cloud-native solution for medical image management.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Jindalee Lithium has successfully raised $1.5 million through an oversubscribed Share Purchase Plan, exceeding its $1 million target to fund the McDermitt Lithium Project and a US SPAC transaction.

HeraMED has secured a pilot agreement with Lee Health, a leading US non-profit health system, to trial its HeraCARE digital maternity platform, aiming to transform prenatal and postpartum care through remote monitoring and virtual engagement.

Airtasker Limited showcased strong FY25 financials and unveiled aggressive growth plans in the UK and US, supported by strategic media partnerships and core platform investments.

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Select Harvests has reported a striking turnaround in FY2025, with net profit soaring to $31.8 million driven by higher almond prices and operational efficiency, while halving its net debt.

Cleo Diagnostics has secured a $1.7 million R&D tax refund, strengthening its cash reserves to $5.75 million as it advances toward a pivotal US clinical trial and FDA submission for its ovarian cancer test.